Replies to post #6518 on $Bob's and Jbem's Bitchin' Bios

[oldberkeley]

See the edit on my prior post, keep researching, just trying to help.

Good summary here:

http://www.fiercebiotech.com/story/athersys-tanks-its-stem-cell-therapy-flunks-phase-ii-stroke-trial/2015-04-17

From the article:

But management, as ever, sees a silver lining in the latest Phase II failure. Dicing up the data after the fact, Athersys notes that patients who got MultiStem earlier in the treatment window did better against the study's endpoints than those who got it later. That group consists of only 27 out of the 65 who got the stem cell treatment, however, and even those results failed to meet statistical significance.